Literature DB >> 3166911

Adjusting survival curves for imbalances in prognostic factors.

W M Gregory1.   

Abstract

A new method for comparing the survival of two or more groups of patients adjusting for factors distributed unevenly between the groups is presented. This is a development of previous methods, and provides a graphical counterpart to Mantel's adjusted chi-square statistic. The method can be used to retrospectively stratify for prognostic factors, and to provide additional validation and interpretation of multivariate results, including those based on Cox's proportional hazards model. Like Mantel's adjusted chi-square statistic, the method adjusts at every event, based on the numbers of patients still at risk in each of the groups, and is thus able to show up time-dependent effects: factors can be seen to be relevant during certain periods of the study only. The method presented thus allows curves to be drawn as they would have been expected to look, had the prognostic factors been evenly distributed between the groups.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166911      PMCID: PMC2246775          DOI: 10.1038/bjc.1988.193

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  7 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Authors:  R Peto; M C Pike
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

3.  Evaluating differences in survival between two groups of patients.

Authors:  B F Hankey; M H Myers
Journal:  J Chronic Dis       Date:  1971-10

4.  Corrected group prognostic curves and summary statistics.

Authors:  I M Chang; R Gelman; M Pagano
Journal:  J Chronic Dis       Date:  1982

5.  Survival analysis by sex, age group and hemotype in sickle cell disease.

Authors:  V K Murthy; L J Haywood
Journal:  J Chronic Dis       Date:  1981

6.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

7.  Adjusted survival curve estimation using covariates.

Authors:  R W Makuch
Journal:  J Chronic Dis       Date:  1982
  7 in total
  7 in total

1.  A new electrocardiogram marker to identify patients at low risk for ventricular tachyarrhythmias: sum magnitude of the absolute QRST integral.

Authors:  Larisa G Tereshchenko; Alan Cheng; Barry J Fetics; Barbara Butcher; Joseph E Marine; David D Spragg; Sunil Sinha; Darshan Dalal; Hugh Calkins; Gordon F Tomaselli; Ronald D Berger
Journal:  J Electrocardiol       Date:  2010-11-20       Impact factor: 1.438

2.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

Review 3.  Statistical aspects of prognostic factor studies in oncology.

Authors:  R Simon; D G Altman
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

4.  High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.

Authors:  C N Harrison; W Gregory; G V Hudson; S Devereux; A H Goldstone; B Hancock; D Winfield; A K MacMillan; P Hoskin; A C Newland; D Milligan; D C Linch
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

5.  High hospital research participation and improved colorectal cancer survival outcomes: a population-based study.

Authors:  Amy Downing; Eva Ja Morris; Neil Corrigan; David Sebag-Montefiore; Paul J Finan; James D Thomas; Michael Chapman; Russell Hamilton; Helen Campbell; David Cameron; Richard Kaplan; Mahesh Parmar; Richard Stephens; Matt Seymour; Walter Gregory; Peter Selby
Journal:  Gut       Date:  2016-10-19       Impact factor: 23.059

6.  The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer.

Authors:  Fiona J Collinson; Walter M Gregory; Chris McCabe; Helen Howard; Catherine Lowe; DrBarbara Potrata; Sandy Tubeuf; Pat Hanlon; Lucy McParland; T Wah; Peter J Selby; Jenny Hewison; Julia Brown; Janet Brown
Journal:  BMC Cancer       Date:  2012-12-14       Impact factor: 4.430

7.  A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report.

Authors:  D C Linch; B Vaughan Hudson; B W Hancock; P J Hoskin; D C Cunningham; A C Newland; D W Milligan; P A Stevenson; J K Wood; K A MacLennan; L Anderson; W M Gregory; G Vaughan Hudson
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.